EcoDrugPlus

Lysyl Oxidase-Like 2a

Ensembl ID : ENSLCRG00005015734
Gene Symbol: LOXL2A
3 Cross references
208 Possible Orthologues:

Lysyl Oxidase-Like 2b

Ensembl ID : ENSLCRG00005017475
Gene Symbol: LOXL2B
3 Cross references
213 Possible Orthologues:

Macrophage Migration Inhibitory Factor

Ensembl ID : ENSLCRG00005008567
Gene Symbol: MIF
3 Cross references
229 Possible Orthologues:

Macrophage Stimulating 1 Receptor B

Ensembl ID : ENSLCRG00005022968
Gene Symbol: MST1RB
2 Cross references
193 Possible Orthologues:

Macrophage-Stimulating Protein Receptor

Ensembl ID : ENSLCRG00005019554
Gene Symbol: LOC104920504
2 Cross references
188 Possible Orthologues:

Mast Cell Protease 1

Ensembl ID : ENSLCRG00005013853
Gene Symbol: LOC109137337
2 Cross references
971 Possible Orthologues:

Matrix Metallopeptidase 14a (Membrane-Inserted)

Ensembl ID : ENSLCRG00005004907
Gene Symbol: MMP14A
3 Cross references
198 Possible Orthologues:

Matrix Metallopeptidase 14b (Membrane-Inserted)

Ensembl ID : ENSLCRG00005007947
Gene Symbol: MMP14B
3 Cross references
196 Possible Orthologues:

Matrix Metallopeptidase 2

Ensembl ID : ENSLCRG00005023354
Gene Symbol: MMP2
3 Cross references
209 Possible Orthologues:

Matrix Metallopeptidase 20a (Enamelysin)

Ensembl ID : ENSLCRG00005011812
Gene Symbol: MMP20A
2 Cross references
163 Possible Orthologues:

Matrix Metallopeptidase 9

Ensembl ID : ENSLCRG00005019979
Gene Symbol: MMP9
3 Cross references
215 Possible Orthologues:

Mechanistic Target Of Rapamycin Kinase

Ensembl ID : ENSLCRG00005006997
Gene Symbol: MTOR
3 Cross references
216 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).